If your healthtech company is selling into the US healthcare market, HIPAA is not optional and it is not a checkbox. Hospital systems, health plans, and digital health platforms will not sign a contract with a vendor that cannot show a working HIPAA compliance program, and their security and legal teams will ask specific, technical questions about how you protect protected health information (PHI). For Canadian and other non-US healthtech companies entering that market, this catches a lot of founders off guard.
Why HIPAA hits healthtech differently
HIPAA was written for a world of paper charts and fax machines, but its enforcement reach now covers cloud-based platforms, APIs, and any vendor that touches PHI on behalf of a covered entity. If your product ingests, stores, transmits, or even just displays patient data for a US hospital, clinic, insurer, or another vendor already covered by HIPAA, you are almost certainly a business associate under the law. That status comes with its own legal obligations, not just a favour you are doing your customer.
The stakes are sector-specific in a few ways that generic compliance frameworks do not capture:
- Business Associate Agreements (BAAs) gate the deal. US healthcare buyers cannot legally sign with you without one, and they will not sign a BAA until they trust your security posture. No BAA usually means no contract, full stop.
- Breach notification rules are unforgiving. A PHI breach triggers notification obligations to patients, HHS, and in some cases the media, on tight timelines. The reputational and legal cost of getting this wrong is much higher than a typical SaaS data incident.
- Data lives everywhere in a healthtech stack. PHI shows up in logs, analytics tools, support tickets, and backups, not just your primary database. A HIPAA program has to account for every place data actually travels, not just the system of record.
- Buyers increasingly ask for HITRUST, but most deals do not require it. HITRUST certification is expensive and can take a year or more. Many healthtech companies lose deals waiting on it when what the buyer actually needed was evidence of a real HIPAA program.
Where founders get this wrong
The most common mistake is treating HIPAA as a legal document exercise: sign a BAA template, write a privacy policy, call it done. HIPAA compliance is an operational program. It requires a risk analysis, documented administrative, physical, and technical safeguards, workforce training, incident response procedures, and evidence that these controls actually run, not just exist on paper. Auditors and enterprise security teams ask for artifacts, not intentions.
The second common mistake is going straight for HITRUST certification because a prospect mentioned it. HITRUST is a valid path for some companies, particularly larger ones selling to payers or hospital systems that mandate it contractually. But for most early and mid-stage healthtech vendors, what actually unblocks a deal is a documented, defensible HIPAA readiness program: policies, a risk assessment, technical safeguards, and a BAA you can stand behind. That is a fraction of the cost and timeline of HITRUST, and it is what most buyers are really asking for when they say "are you HIPAA compliant."
How traztech scopes HIPAA readiness for healthtech
traztech runs HIPAA compliance readiness for digital health companies selling into the US healthcare market. We deliberately do not sell full HITRUST certification. Our engagement builds the readiness layer underneath it: a HIPAA risk assessment specific to your architecture, the administrative and technical safeguards you need to implement, policy documentation your legal team and enterprise buyers can review, and a BAA-ready posture you can point to in security questionnaires.
The part that saves healthtech companies real time and money is how we sequence this against SOC 2. Most US healthcare buyers, especially digital health platforms and health systems procuring software, ask for both SOC 2 and HIPAA evidence in the same due diligence cycle. The two frameworks overlap heavily on access control, encryption, incident response, and vendor management. Building them separately means redoing the same evidence twice, on two different timelines, with two different consultants who are not talking to each other.
We run HIPAA readiness alongside SOC 2 so the underlying control evidence gets built once and mapped to both frameworks. That means one risk assessment process, one set of policies drafted to satisfy both sets of requirements, and one evidence collection cycle instead of two. For a healthtech company trying to close US healthcare deals on a real timeline, that consolidation is often the difference between a six-month compliance sprint and a twelve-month one.
Who this is for
This engagement fits Canadian and other international healthtech companies expanding into the US, digital health startups building their first real compliance program ahead of enterprise sales, and healthtech platforms that have outgrown a patchwork of policy templates and self-attestations. If your sales team is fielding HIPAA questions in every deal cycle and you do not have a documented answer beyond "we take security seriously," that is the signal it is time to scope this properly.
It is worth pairing HIPAA readiness with a broader look at your compliance program as a whole, particularly if SOC 2, PIPEDA, or other frameworks are also on your roadmap. Getting the sequencing right across frameworks is where most of the cost savings live.
What this is not
To be direct about scope: this is not HITRUST certification, and it is not a substitute for legal review of your BAAs and contracts. What it is: a practical, evidence-based HIPAA readiness program built by a team that understands how US healthcare buyers actually evaluate vendors, scoped to get you deal-ready without the cost and timeline of a certification most of your buyers are not actually requiring.
If you are a healthtech company selling into US healthcare and need a HIPAA program that stands up to buyer scrutiny, without overbuilding for a certification you do not need yet, get in touch and we will walk through how your architecture and sales pipeline should shape the scope.